{
    "code": "02021439",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02021439",
    "time": "2022-01-14 07:13:10",
    "許可證字號": "衛署藥輸字第021439號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "110\/11\/19",
    "發證\/登錄日期": "85\/11\/19",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202143901",
    "中文品名": "安室律注射劑３公絲／公撮",
    "英文品名": "ADENOCOR INJECTION 3MG\/ML",
    "適應症": "治療陣發性上心室心搏過速、輔助診斷ＱＲＳ波變寬或變窄之複雜性上心室心搏過速",
    "劑型": "270注射劑",
    "包裝": "小瓶 盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "92\/11\/19",
    "主成分略述": "ADENOSINE",
    "限制項目": "02輸　入",
    "申請商名稱": "1424601100  賽諾菲股份有限公司",
    "申請商地址": "台北市信義區松仁路3號7樓",
    "主製造廠": [
        {
            "": "SPAIN",
            "製程": ""
        }
    ],
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200000300",
            "成分名稱": "ADENOSINE",
            "含量描述": "",
            "含量": "3.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Adenocor_leaflet_C_CCDS v8_approved-104-03-03.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02021439&Seq=007&Type=9"
        },
        {
            "title": "020214390003___20110705.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02021439&Seq=005&Type=8"
        }
    ]
}